Navigation Links
Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
Date:10/30/2008

amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Pheromone Sciences, Inc. - Shareholder Update
2. The human brain minimizes energy expenditure and integrates gravity in to the action plan
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs
5. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
6. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
8. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
9. Pigs bred with cystic fibrosis provide model to mimic human disease
10. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: IPXL).  Such investors are advised to contact ... 888-476-6529, ext. 237. The investigation concerns whether ... violated Sections 10(b) and 20(a) of the Securities Exchange ... 2014, Impax Laboratories, Inc. (the "Company") issued a press ...
(Date:7/29/2014)... 29, 2014 According to the ... Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud ... & Trends to 2018", published by MarketsandMarkets, analyzes and ... such as North America , ... and the Rest of the World (RoW). ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, applauds the Editorial ... a strong position in opposition to current federal ... 2014 publication.  The New York Times also announces ... week exploring the issue called "High Time:  An ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... First Capability To Rapidly Identify Five Candida ... Positive Blood Cultures In One Test, WOBURN, ... FDA 510(k) clearance of the Yeast Traffic Light ... positive blood cultures. The,Yeast Traffic Light(TM) is the ...
... 23 Affitech AS, the Norwegian human,antibody ... accomplished the,second milestone in its research and ... recombinant antibodies against an unnamed oncology,target. Affitech ... Antibody,Screening) system that included its proprietary antibody ...
... 22, 2008 -- Chemists at Rice University have discovered ... tiny, wand-like nanoparticles that are being studied in dozens ... disease and improving electronic viewscreens. , "The content of ... is only about 20 percent," said lead researcher Eugene ...
Cached Biology Technology:AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2Purifying nanorods: Big success with tiny cleanup 2
(Date:7/28/2014)... of people in the United States have a circulatory ... can be painful and may even require surgery in ... muscle wasting and, in turn, limb amputation. , At ... (UTHealth) Medical School, scientists tested a non-surgical preventative treatment ... was associated with increased blood circulation. Their proof-of-concept ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the ... of researchers including the labs headed by Professors Neelima ... of Plant Biology. The new genome information may help ... published July 27 in the journal Nature Genetics ... Aachen University in Germany. The UC Davis labs carried ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... buzzing around your plate. Its color and motion could both influence ... might decide it was a bee and move away. Conversely, you ... insect away. You perceive both color and motion, and decide based ... heartbeat. The mystery is how. In an article published November ...
... A human clinical study of older adults has demonstrated ... dietary supplement created by Natura Therapeutics, Inc., showed ... individuals taking a placebo. Cognition includes processes such as ... The company,s study, Nutraceutical Intervention Improves Older Adults, Cognitive ...
... early infancy may be a key to early identification of ... of Mental Health (NIMH), part of the National Institutes of ... the study reveals the earliest sign of developing autism ever ... first two to six months of life. "Autism ...
Cached Biology News:Stanford researchers surprised to find how neural circuits identify information needed for decisions 2Stanford researchers surprised to find how neural circuits identify information needed for decisions 3Stanford researchers surprised to find how neural circuits identify information needed for decisions 4Stanford researchers surprised to find how neural circuits identify information needed for decisions 5Natura Therapeutics product shown to improve decision making skills in older adults 2Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Human LAIR2 Biotinylated Affinity Purified PAb...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: